Macular Degeneration Treatment Market By Type (Dry Age Related Macular Degeneration, Wet Age-Related Macular Degeneration) , By Stage Of Disease (Early Stage AMD, Intermediate Stage AMD, Late Stage AMD) By Route Of Administration (Intravenous, Intravitrea

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,425	295 Pages	Allied Market Research	August, 2024	ALMR19510226

Best Price Guarantee
Price	from $4,425
Length	295 Pages
Publisher	Allied Market Research
Published Date	August, 2024
SKU	ALMR19510226

Macular Degeneration Treatment Market By Type (Dry Age Related Macular Degeneration, Wet Age-Related Macular Degeneration) , By Stage Of Disease (Early Stage AMD, Intermediate Stage AMD, Late Stage AMD) By Route Of Administration (Intravenous, Intravitreal) By End User (Hospitals and Clinics, Ambulatory Surgical Center, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Macular Degeneration Treatment Market Expected to Generate $30.9 Billion by 2033, Growing with a CAGR of 8.2%

The global macular degeneration treatment market is expected to grow primarily due to the growing prevalence of macular degeneration worldwide due to sedentary lifestyles, obesity, and poor dietary choices. The market in the North America region is predicted to grow with the highest profitability.

As per the report published by Research Dive, the global macular degeneration treatment market was valued at $14.3 billion in 2023 and is expected to register a revenue of $30.9 billion by 2033 at a CAGR of 8.2% during the forecast period 2024-2033.

Dynamics of the Market

The growing number of patients diagnosed with retinal disorders, increasing elderly population, and the rising awareness about macular degeneration treatment are expected to make the macular degeneration treatment market a highly profitable one in the forecast period. Besides, the rising healthcare spending facilitates expanded accessibility to treatments for macular degeneration.

However, according to market analysts, the high cost and healthcare complications associated with macular degeneration treatment might restraint the growth of the market.

The rapid advancement of novel treatments, such as gene therapy and stem cell research is predicted to offer numerous growth opportunities to the market in the forecast period. Moreover, the favorable regulatory environments that aid in developing and launching new therapies is expected to propel the macular degeneration treatment market forward in the coming period.

Key Players of the Market

The major players of the macular degeneration market include REGENXBIO Inc., Panoptica, Regeneron, Novartis AG, Pfizer Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche AG, Thermo Fischer Scientific, Inc., Astellas Pharma Inc., and Aerie Pharmaceutical Inc.

What the Report Covers

In addition to the details highlighted in this description, the comprehensive final report delves into essential market aspects. These encompass a market overview, SWOT analysis, market dynamics, Porter’s five forces analysis, segmentation (key trends, regional analysis, and forecast analysis), and company profiles (including company overview, product portfolio, operating segments, strategic initiatives, and financial performance).

Key Market Segments

By Type

Dry Age Related Macular Degeneration
Wet Age-Related Macular Degeneration

By Stage Of Disease

Early Stage AMD
Intermediate Stage AMD
Late Stage AMD

By Route Of Administration

Intravenous
Intravitreal

By End User

Hospitals and Clinics
Ambulatory Surgical Center
Others

By Region

North America
U.S.
Canada
Mexico
Europe
France
Germany
Italy
Spain
UK
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
UAE
Rest of LAMEA

Key Market Players

REGENXBIO Inc.
Regeneron
Panoptica
Novartis AG
Bausch Health Companies Inc
Pfizer Inc.
F. Hoffmann-La Roche AG
Astellas Pharma Inc.
Thermo Fischer Scientific, Inc.
Aerie Pharmaceutical Inc.

CHAPTER 1: INTRODUCTION: 1.1. Report Description; 1.2. Key Market Segments; 1.3. Key Benefits; 1.4. Research Methodology; 1.4.1. Primary Research; 1.4.2. Secondary Research; 1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY: 2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE: 3.1. Market Definition and Scope; 3.2. Key Findings; 3.2.1. Top Investment Pockets; 3.2.2. Top Winning Strategies; 3.3. Porter's Five Forces Analysis; 3.3.1. Bargaining Power of Suppliers; 3.3.2. Threat of New Entrants; 3.3.3. Threat of Substitutes; 3.3.4. Competitive Rivalry; 3.3.5. Bargaining Power among Buyers; 3.4. Market Dynamics; 3.4.1. Drivers; 3.4.2. Restraints; 3.4.3. Opportunities
CHAPTER 4: MACULAR DEGENERATION TREATMENT MARKET, BY TYPE: 4.1. Market Overview; 4.1.1 Market Size and Forecast, By Type; 4.2. Dry Age Related Macular Degeneration; 4.2.1. Key Market Trends, Growth Factors and Opportunities; 4.2.2. Market Size and Forecast, By Region; 4.2.3. Market Share Analysis, By Country; 4.3. Wet Age-Related Macular Degeneration; 4.3.1. Key Market Trends, Growth Factors and Opportunities; 4.3.2. Market Size and Forecast, By Region; 4.3.3. Market Share Analysis, By Country
CHAPTER 5: MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE: 5.1. Market Overview; 5.1.1 Market Size and Forecast, By Stage Of Disease; 5.2. Early Stage AMD; 5.2.1. Key Market Trends, Growth Factors and Opportunities; 5.2.2. Market Size and Forecast, By Region; 5.2.3. Market Share Analysis, By Country; 5.3. Intermediate Stage AMD; 5.3.1. Key Market Trends, Growth Factors and Opportunities; 5.3.2. Market Size and Forecast, By Region; 5.3.3. Market Share Analysis, By Country; 5.4. Late Stage AMD; 5.4.1. Key Market Trends, Growth Factors and Opportunities; 5.4.2. Market Size and Forecast, By Region; 5.4.3. Market Share Analysis, By Country
CHAPTER 6: MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION: 6.1. Market Overview; 6.1.1 Market Size and Forecast, By Route Of Administration; 6.2. Intravenous; 6.2.1. Key Market Trends, Growth Factors and Opportunities; 6.2.2. Market Size and Forecast, By Region; 6.2.3. Market Share Analysis, By Country; 6.3. Intravitreal; 6.3.1. Key Market Trends, Growth Factors and Opportunities; 6.3.2. Market Size and Forecast, By Region; 6.3.3. Market Share Analysis, By Country
CHAPTER 7: MACULAR DEGENERATION TREATMENT MARKET, BY END USER: 7.1. Market Overview; 7.1.1 Market Size and Forecast, By End User; 7.2. Hospitals And Clinics; 7.2.1. Key Market Trends, Growth Factors and Opportunities; 7.2.2. Market Size and Forecast, By Region; 7.2.3. Market Share Analysis, By Country; 7.3. Ambulatory Surgical Center; 7.3.1. Key Market Trends, Growth Factors and Opportunities; 7.3.2. Market Size and Forecast, By Region; 7.3.3. Market Share Analysis, By Country; 7.4. Others; 7.4.1. Key Market Trends, Growth Factors and Opportunities; 7.4.2. Market Size and Forecast, By Region; 7.4.3. Market Share Analysis, By Country
CHAPTER 8: MACULAR DEGENERATION TREATMENT MARKET, BY REGION: 8.1. Market Overview; 8.1.1 Market Size and Forecast, By Region; 8.2. North America; 8.2.1. Key Market Trends and Opportunities; 8.2.2. Market Size and Forecast, By Type; 8.2.3. Market Size and Forecast, By Stage Of Disease; 8.2.4. Market Size and Forecast, By Route Of Administration; 8.2.5. Market Size and Forecast, By End User; 8.2.6. Market Size and Forecast, By Country; 8.2.7. U.S. Macular Degeneration Treatment Market; 8.2.7.1. Market Size and Forecast, By Type; 8.2.7.2. Market Size and Forecast, By Stage Of Disease; 8.2.7.3. Market Size and Forecast, By Route Of Administration; 8.2.7.4. Market Size and Forecast, By End User; 8.2.8. Canada Macular Degeneration Treatment Market; 8.2.8.1. Market Size and Forecast, By Type; 8.2.8.2. Market Size and Forecast, By Stage Of Disease; 8.2.8.3. Market Size and Forecast, By Route Of Administration; 8.2.8.4. Market Size and Forecast, By End User; 8.2.9. Mexico Macular Degeneration Treatment Market; 8.2.9.1. Market Size and Forecast, By Type; 8.2.9.2. Market Size and Forecast, By Stage Of Disease; 8.2.9.3. Market Size and Forecast, By Route Of Administration; 8.2.9.4. Market Size and Forecast, By End User; 8.3. Europe; 8.3.1. Key Market Trends and Opportunities; 8.3.2. Market Size and Forecast, By Type; 8.3.3. Market Size and Forecast, By Stage Of Disease; 8.3.4. Market Size and Forecast, By Route Of Administration; 8.3.5. Market Size and Forecast, By End User; 8.3.6. Market Size and Forecast, By Country; 8.3.7. France Macular Degeneration Treatment Market; 8.3.7.1. Market Size and Forecast, By Type; 8.3.7.2. Market Size and Forecast, By Stage Of Disease; 8.3.7.3. Market Size and Forecast, By Route Of Administration; 8.3.7.4. Market Size and Forecast, By End User; 8.3.8. Germany Macular Degeneration Treatment Market; 8.3.8.1. Market Size and Forecast, By Type; 8.3.8.2. Market Size and Forecast, By Stage Of Disease; 8.3.8.3. Market Size and Forecast, By Route Of Administration; 8.3.8.4. Market Size and Forecast, By End User; 8.3.9. Italy Macular Degeneration Treatment Market; 8.3.9.1. Market Size and Forecast, By Type; 8.3.9.2. Market Size and Forecast, By Stage Of Disease; 8.3.9.3. Market Size and Forecast, By Route Of Administration; 8.3.9.4. Market Size and Forecast, By End User; 8.3.10. Spain Macular Degeneration Treatment Market; 8.3.10.1. Market Size and Forecast, By Type; 8.3.10.2. Market Size and Forecast, By Stage Of Disease; 8.3.10.3. Market Size and Forecast, By Route Of Administration; 8.3.10.4. Market Size and Forecast, By End User; 8.3.11. UK Macular Degeneration Treatment Market; 8.3.11.1. Market Size and Forecast, By Type; 8.3.11.2. Market Size and Forecast, By Stage Of Disease; 8.3.11.3. Market Size and Forecast, By Route Of Administration; 8.3.11.4. Market Size and Forecast, By End User; 8.3.12. Rest Of Europe Macular Degeneration Treatment Market; 8.3.12.1. Market Size and Forecast, By Type; 8.3.12.2. Market Size and Forecast, By Stage Of Disease; 8.3.12.3. Market Size and Forecast, By Route Of Administration; 8.3.12.4. Market Size and Forecast, By End User; 8.4. Asia-Pacific; 8.4.1. Key Market Trends and Opportunities; 8.4.2. Market Size and Forecast, By Type; 8.4.3. Market Size and Forecast, By Stage Of Disease; 8.4.4. Market Size and Forecast, By Route Of Administration; 8.4.5. Market Size and Forecast, By End User; 8.4.6. Market Size and Forecast, By Country; 8.4.7. China Macular Degeneration Treatment Market; 8.4.7.1. Market Size and Forecast, By Type; 8.4.7.2. Market Size and Forecast, By Stage Of Disease; 8.4.7.3. Market Size and Forecast, By Route Of Administration; 8.4.7.4. Market Size and Forecast, By End User; 8.4.8. Japan Macular Degeneration Treatment Market; 8.4.8.1. Market Size and Forecast, By Type; 8.4.8.2. Market Size and Forecast, By Stage Of Disease; 8.4.8.3. Market Size and Forecast, By Route Of Administration; 8.4.8.4. Market Size and Forecast, By End User; 8.4.9. India Macular Degeneration Treatment Market; 8.4.9.1. Market Size and Forecast, By Type; 8.4.9.2. Market Size and Forecast, By Stage Of Disease; 8.4.9.3. Market Size and Forecast, By Route Of Administration; 8.4.9.4. Market Size and Forecast, By End User; 8.4.10. South Korea Macular Degeneration Treatment Market; 8.4.10.1. Market Size and Forecast, By Type; 8.4.10.2. Market Size and Forecast, By Stage Of Disease; 8.4.10.3. Market Size and Forecast, By Route Of Administration; 8.4.10.4. Market Size and Forecast, By End User; 8.4.11. Australia Macular Degeneration Treatment Market; 8.4.11.1. Market Size and Forecast, By Type; 8.4.11.2. Market Size and Forecast, By Stage Of Disease; 8.4.11.3. Market Size and Forecast, By Route Of Administration; 8.4.11.4. Market Size and Forecast, By End User; 8.4.12. Rest of Asia-Pacific Macular Degeneration Treatment Market; 8.4.12.1. Market Size and Forecast, By Type; 8.4.12.2. Market Size and Forecast, By Stage Of Disease; 8.4.12.3. Market Size and Forecast, By Route Of Administration; 8.4.12.4. Market Size and Forecast, By End User; 8.5. LAMEA; 8.5.1. Key Market Trends and Opportunities; 8.5.2. Market Size and Forecast, By Type; 8.5.3. Market Size and Forecast, By Stage Of Disease; 8.5.4. Market Size and Forecast, By Route Of Administration; 8.5.5. Market Size and Forecast, By End User; 8.5.6. Market Size and Forecast, By Country; 8.5.7. Brazil Macular Degeneration Treatment Market; 8.5.7.1. Market Size and Forecast, By Type; 8.5.7.2. Market Size and Forecast, By Stage Of Disease; 8.5.7.3. Market Size and Forecast, By Route Of Administration; 8.5.7.4. Market Size and Forecast, By End User; 8.5.8. South Africa Macular Degeneration Treatment Market; 8.5.8.1. Market Size and Forecast, By Type; 8.5.8.2. Market Size and Forecast, By Stage Of Disease; 8.5.8.3. Market Size and Forecast, By Route Of Administration; 8.5.8.4. Market Size and Forecast, By End User; 8.5.9. Saudi Arabia Macular Degeneration Treatment Market; 8.5.9.1. Market Size and Forecast, By Type; 8.5.9.2. Market Size and Forecast, By Stage Of Disease; 8.5.9.3. Market Size and Forecast, By Route Of Administration; 8.5.9.4. Market Size and Forecast, By End User; 8.5.10. UAE Macular Degeneration Treatment Market; 8.5.10.1. Market Size and Forecast, By Type; 8.5.10.2. Market Size and Forecast, By Stage Of Disease; 8.5.10.3. Market Size and Forecast, By Route Of Administration; 8.5.10.4. Market Size and Forecast, By End User; 8.5.11. Rest of LAMEA Macular Degeneration Treatment Market; 8.5.11.1. Market Size and Forecast, By Type; 8.5.11.2. Market Size and Forecast, By Stage Of Disease; 8.5.11.3. Market Size and Forecast, By Route Of Administration; 8.5.11.4. Market Size and Forecast, By End User
CHAPTER 9: COMPETITIVE LANDSCAPE: 9.1. Introduction; 9.2. Top Winning Strategies; 9.3. Product Mapping Of Top 10 Player; 9.4. Competitive Dashboard; 9.5. Competitive Heatmap; 9.6. Top Player Positioning, 2023
CHAPTER 10: COMPANY PROFILES: 10.1. REGENXBIO Inc.; 10.1.1. Company Overview; 10.1.2. Key Executives; 10.1.3. Company Snapshot; 10.1.4. Operating Business Segments; 10.1.5. Product Portfolio; 10.1.6. Business Performance; 10.1.7. Key Strategic Moves and Developments; 10.2. Regeneron; 10.2.1. Company Overview; 10.2.2. Key Executives; 10.2.3. Company Snapshot; 10.2.4. Operating Business Segments; 10.2.5. Product Portfolio; 10.2.6. Business Performance; 10.2.7. Key Strategic Moves and Developments; 10.3. Panoptica; 10.3.1. Company Overview; 10.3.2. Key Executives; 10.3.3. Company Snapshot; 10.3.4. Operating Business Segments; 10.3.5. Product Portfolio; 10.3.6. Business Performance; 10.3.7. Key Strategic Moves and Developments; 10.4. Novartis AG; 10.4.1. Company Overview; 10.4.2. Key Executives; 10.4.3. Company Snapshot; 10.4.4. Operating Business Segments; 10.4.5. Product Portfolio; 10.4.6. Business Performance; 10.4.7. Key Strategic Moves and Developments; 10.5. Bausch Health Companies Inc; 10.5.1. Company Overview; 10.5.2. Key Executives; 10.5.3. Company Snapshot; 10.5.4. Operating Business Segments; 10.5.5. Product Portfolio; 10.5.6. Business Performance; 10.5.7. Key Strategic Moves and Developments; 10.6. Pfizer Inc.; 10.6.1. Company Overview; 10.6.2. Key Executives; 10.6.3. Company Snapshot; 10.6.4. Operating Business Segments; 10.6.5. Product Portfolio; 10.6.6. Business Performance; 10.6.7. Key Strategic Moves and Developments; 10.7. F. Hoffmann-La Roche AG; 10.7.1. Company Overview; 10.7.2. Key Executives; 10.7.3. Company Snapshot; 10.7.4. Operating Business Segments; 10.7.5. Product Portfolio; 10.7.6. Business Performance; 10.7.7. Key Strategic Moves and Developments; 10.8. Astellas Pharma Inc.; 10.8.1. Company Overview; 10.8.2. Key Executives; 10.8.3. Company Snapshot; 10.8.4. Operating Business Segments; 10.8.5. Product Portfolio; 10.8.6. Business Performance; 10.8.7. Key Strategic Moves and Developments; 10.9. Thermo Fischer Scientific, Inc.; 10.9.1. Company Overview; 10.9.2. Key Executives; 10.9.3. Company Snapshot; 10.9.4. Operating Business Segments; 10.9.5. Product Portfolio; 10.9.6. Business Performance; 10.9.7. Key Strategic Moves and Developments; 10.10. Aerie Pharmaceutical Inc.; 10.10.1. Company Overview; 10.10.2. Key Executives; 10.10.3. Company Snapshot; 10.10.4. Operating Business Segments; 10.10.5. Product Portfolio; 10.10.6. Business Performance; 10.10.7. Key Strategic Moves and Developments
LIST OF TABLES: TABLE 1. GLOBAL MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 2. MACULAR DEGENERATION TREATMENT MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY REGION, 2024 - 2033 ($BILLION); TABLE 3. MACULAR DEGENERATION TREATMENT MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2024 - 2033 ($BILLION); TABLE 4. GLOBAL MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 5. MACULAR DEGENERATION TREATMENT MARKET FOR EARLY STAGE AMD, BY REGION, 2024 - 2033 ($BILLION); TABLE 6. MACULAR DEGENERATION TREATMENT MARKET FOR INTERMEDIATE STAGE AMD, BY REGION, 2024 - 2033 ($BILLION); TABLE 7. MACULAR DEGENERATION TREATMENT MARKET FOR LATE STAGE AMD, BY REGION, 2024 - 2033 ($BILLION); TABLE 8. GLOBAL MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 9. MACULAR DEGENERATION TREATMENT MARKET FOR INTRAVENOUS, BY REGION, 2024 - 2033 ($BILLION); TABLE 10. MACULAR DEGENERATION TREATMENT MARKET FOR INTRAVITREAL, BY REGION, 2024 - 2033 ($BILLION); TABLE 11. GLOBAL MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 12. MACULAR DEGENERATION TREATMENT MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2024 - 2033 ($BILLION); TABLE 13. MACULAR DEGENERATION TREATMENT MARKET FOR AMBULATORY SURGICAL CENTER, BY REGION, 2024 - 2033 ($BILLION); TABLE 14. MACULAR DEGENERATION TREATMENT MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION); TABLE 15. MACULAR DEGENERATION TREATMENT MARKET, BY REGION, 2024 - 2033 ($BILLION); TABLE 16. NORTH AMERICA MACULAR DEGENERATION TREATMENT MARKET, BY COUNTRY, 2024 - 2033 ($BILLION); TABLE 17. NORTH AMERICA MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 18. NORTH AMERICA MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 19. NORTH AMERICA MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 20. NORTH AMERICA MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 21. U.S. MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 22. U.S. MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 23. U.S. MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 24. U.S. MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 25. CANADA MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 26. CANADA MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 27. CANADA MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 28. CANADA MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 29. MEXICO MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 30. MEXICO MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 31. MEXICO MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 32. MEXICO MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 33. EUROPE MACULAR DEGENERATION TREATMENT MARKET, BY COUNTRY, 2024 - 2033 ($BILLION); TABLE 34. EUROPE MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 35. EUROPE MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 36. EUROPE MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 37. EUROPE MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 38. FRANCE MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 39. FRANCE MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 40. FRANCE MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 41. FRANCE MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 42. GERMANY MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 43. GERMANY MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 44. GERMANY MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 45. GERMANY MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 46. ITALY MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 47. ITALY MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 48. ITALY MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 49. ITALY MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 50. SPAIN MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 51. SPAIN MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 52. SPAIN MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 53. SPAIN MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 54. UK MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 55. UK MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 56. UK MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 57. UK MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 58. REST OF EUROPE MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 59. REST OF EUROPE MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 60. REST OF EUROPE MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 61. REST OF EUROPE MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 62. ASIA-PACIFIC MACULAR DEGENERATION TREATMENT MARKET, BY COUNTRY, 2024 - 2033 ($BILLION); TABLE 63. ASIA-PACIFIC MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 64. ASIA-PACIFIC MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 65. ASIA-PACIFIC MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 66. ASIA-PACIFIC MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 67. CHINA MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 68. CHINA MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 69. CHINA MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 70. CHINA MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 71. JAPAN MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 72. JAPAN MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 73. JAPAN MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 74. JAPAN MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 75. INDIA MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 76. INDIA MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 77. INDIA MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 78. INDIA MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 79. SOUTH KOREA MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 80. SOUTH KOREA MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 81. SOUTH KOREA MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 82. SOUTH KOREA MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 83. AUSTRALIA MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 84. AUSTRALIA MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 85. AUSTRALIA MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 86. AUSTRALIA MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 87. REST OF ASIA-PACIFIC MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 88. REST OF ASIA-PACIFIC MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 89. REST OF ASIA-PACIFIC MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 90. REST OF ASIA-PACIFIC MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 91. LAMEA MACULAR DEGENERATION TREATMENT MARKET, BY COUNTRY, 2024 - 2033 ($BILLION); TABLE 92. LAMEA MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 93. LAMEA MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 94. LAMEA MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 95. LAMEA MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 96. BRAZIL MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 97. BRAZIL MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 98. BRAZIL MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 99. BRAZIL MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 100. SOUTH AFRICA MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 101. SOUTH AFRICA MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 102. SOUTH AFRICA MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 103. SOUTH AFRICA MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 104. SAUDI ARABIA MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 105. SAUDI ARABIA MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 106. SAUDI ARABIA MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 107. SAUDI ARABIA MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 108. UAE MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 109. UAE MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 110. UAE MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 111. UAE MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 112. REST OF LAMEA MACULAR DEGENERATION TREATMENT MARKET, BY TYPE, 2024 - 2033 ($BILLION); TABLE 113. REST OF LAMEA MACULAR DEGENERATION TREATMENT MARKET, BY STAGE OF DISEASE, 2024 - 2033 ($BILLION); TABLE 114. REST OF LAMEA MACULAR DEGENERATION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION); TABLE 115. REST OF LAMEA MACULAR DEGENERATION TREATMENT MARKET, BY END USER, 2024 - 2033 ($BILLION); TABLE 116. REGENXBIO INC.: KEY EXECUTIVES; TABLE 117. REGENXBIO INC.: COMPANY SNAPSHOT; TABLE 118. REGENXBIO INC.: OPERATING SEGMENTS; TABLE 119. REGENXBIO INC.: PRODUCT PORTFOLIO; TABLE 120. REGENXBIO INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 121. REGENERON: KEY EXECUTIVES; TABLE 122. REGENERON: COMPANY SNAPSHOT; TABLE 123. REGENERON: OPERATING SEGMENTS; TABLE 124. REGENERON: PRODUCT PORTFOLIO; TABLE 125. REGENERON: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 126. PANOPTICA: KEY EXECUTIVES; TABLE 127. PANOPTICA: COMPANY SNAPSHOT; TABLE 128. PANOPTICA: OPERATING SEGMENTS; TABLE 129. PANOPTICA: PRODUCT PORTFOLIO; TABLE 130. PANOPTICA: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 131. NOVARTIS AG: KEY EXECUTIVES; TABLE 132. NOVARTIS AG: COMPANY SNAPSHOT; TABLE 133. NOVARTIS AG: OPERATING SEGMENTS; TABLE 134. NOVARTIS AG: PRODUCT PORTFOLIO; TABLE 135. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 136. BAUSCH HEALTH COMPANIES INC: KEY EXECUTIVES; TABLE 137. BAUSCH HEALTH COMPANIES INC: COMPANY SNAPSHOT; TABLE 138. BAUSCH HEALTH COMPANIES INC: OPERATING SEGMENTS; TABLE 139. BAUSCH HEALTH COMPANIES INC: PRODUCT PORTFOLIO; TABLE 140. BAUSCH HEALTH COMPANIES INC: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 141. PFIZER INC.: KEY EXECUTIVES; TABLE 142. PFIZER INC.: COMPANY SNAPSHOT; TABLE 143. PFIZER INC.: OPERATING SEGMENTS; TABLE 144. PFIZER INC.: PRODUCT PORTFOLIO; TABLE 145. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 146. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES; TABLE 147. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT; TABLE 148. F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS; TABLE 149. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO; TABLE 150. F. HOFFMANN-LA ROCHE AG: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 151. ASTELLAS PHARMA INC.: KEY EXECUTIVES; TABLE 152. ASTELLAS PHARMA INC.: COMPANY SNAPSHOT; TABLE 153. ASTELLAS PHARMA INC.: OPERATING SEGMENTS; TABLE 154. ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO; TABLE 155. ASTELLAS PHARMA INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 156. THERMO FISCHER SCIENTIFIC, INC.: KEY EXECUTIVES; TABLE 157. THERMO FISCHER SCIENTIFIC, INC.: COMPANY SNAPSHOT; TABLE 158. THERMO FISCHER SCIENTIFIC, INC.: OPERATING SEGMENTS; TABLE 159. THERMO FISCHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO; TABLE 160. THERMO FISCHER SCIENTIFIC, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 161. AERIE PHARMACEUTICAL INC.: KEY EXECUTIVES; TABLE 162. AERIE PHARMACEUTICAL INC.: COMPANY SNAPSHOT; TABLE 163. AERIE PHARMACEUTICAL INC.: OPERATING SEGMENTS; TABLE 164. AERIE PHARMACEUTICAL INC.: PRODUCT PORTFOLIO; TABLE 165. AERIE PHARMACEUTICAL INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES: FIGURE 1. GLOBAL MACULAR DEGENERATION TREATMENT MARKET, 2024 - 2033; FIGURE 2. SEGMENTATION OF MACULAR DEGENERATION TREATMENT MARKET, 2024 - 2033; FIGURE 3. TOP INVESTMENT POCKET IN MACULAR DEGENERATION TREATMENT MARKET; FIGURE 4. MODERATE BARGAINING POWER OF BUYERS; FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS; FIGURE 6. MODERATE THREAT OF NEW ENTRANTS; FIGURE 7. LOW THREAT OF SUBSTITUTION; FIGURE 8. HIGH COMPETITIVE RIVALRY; FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALMACULAR DEGENERATION TREATMENT MARKET; FIGURE 10. GLOBAL MACULAR DEGENERATION TREATMENT MARKET SEGMENTATION, BY TYPE; FIGURE 11. MACULAR DEGENERATION TREATMENT MARKET FOR DRY AGE RELATED MACULAR DEGENERATION, BY COUNTRY, 2024 - 2033 ($BILLION); FIGURE 12. MACULAR DEGENERATION TREATMENT MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2024 - 2033 ($BILLION); FIGURE 13. GLOBAL MACULAR DEGENERATION TREATMENT MARKET SEGMENTATION, BY STAGE OF DISEASE; FIGURE 14. MACULAR DEGENERATION TREATMENT MARKET FOR EARLY STAGE AMD, BY COUNTRY, 2024 - 2033 ($BILLION); FIGURE 15. MACULAR DEGENERATION TREATMENT MARKET FOR INTERMEDIATE STAGE AMD, BY COUNTRY, 2024 - 2033 ($BILLION); FIGURE 16. MACULAR DEGENERATION TREATMENT MARKET FOR LATE STAGE AMD, BY COUNTRY, 2024 - 2033 ($BILLION); FIGURE 17. GLOBAL MACULAR DEGENERATION TREATMENT MARKET SEGMENTATION, BY ROUTE OF ADMINISTRATION; FIGURE 18. MACULAR DEGENERATION TREATMENT MARKET FOR INTRAVENOUS, BY COUNTRY, 2024 - 2033 ($BILLION); FIGURE 19. MACULAR DEGENERATION TREATMENT MARKET FOR INTRAVITREAL, BY COUNTRY, 2024 - 2033 ($BILLION); FIGURE 20. GLOBAL MACULAR DEGENERATION TREATMENT MARKET SEGMENTATION, BY END USER; FIGURE 21. MACULAR DEGENERATION TREATMENT MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2024 - 2033 ($BILLION); FIGURE 22. MACULAR DEGENERATION TREATMENT MARKET FOR AMBULATORY SURGICAL CENTER, BY COUNTRY, 2024 - 2033 ($BILLION); FIGURE 23. MACULAR DEGENERATION TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION); FIGURE 24. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*; FIGURE 25. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*; FIGURE 26. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*; FIGURE 27. PRODUCT MAPPING OF TOP 10 PLAYERS; FIGURE 28. COMPETITIVE DASHBOARD; FIGURE 29. COMPETITIVE HEATMAP: MACULAR DEGENERATION TREATMENT MARKET; FIGURE 30. TOP PLAYER POSITIONING, 2023; FIGURE 31. REGENXBIO INC.: NET SALES, 2021-2023 ($BILLION); FIGURE 32. REGENXBIO INC.: REVENUE SHARE, BY SEGMENT, 2023 (%); FIGURE 33. REGENXBIO INC.: REVENUE SHARE, BY REGION, 2023 (%); FIGURE 34. REGENERON: NET SALES, 2021-2023 ($BILLION)